Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

Medtronic initially secured FDA clearance for the MiniMed 780G pump for people with Type 1 diabetes in early 2023. This past ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | ...

As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer ...

J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

Pharma marketers enter 2026 asking where DTC fits in the DTP era.  | Pharma marketers enter 2026 asking where DTC fits in the ...

“Healthcare and pharma are steadily moving past a TV-first mindset. While linear TV made up more than 30% of the industry’s ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...